These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of terazosin on serum lipids.
    Author: Deger G.
    Journal: Am J Med; 1986 May 23; 80(5B):82-5. PubMed ID: 2872813.
    Abstract:
    The effect of terazosin administration on serum lipid profiles was assessed in four multicenter, randomized, controlled, double-blind studies in which patients were treated for mild to moderate hypertension. Three studies were placebo-controlled, fixed-dose studies in which the dose of terazosin was gradually increased to a fixed level of 5, 10, or 20 mg once daily, and remained fixed for four weeks. The remaining study was a placebo-controlled, dose-titration study designed to compare the antihypertensive effects of once-daily administration of terazosin with those of twice-daily administration of prazosin. In this study, the dosage of medication was titrated until a satisfactory decrease in supine diastolic blood pressure was obtained, or until the maximum daily dosage (20 mg) was reached. When data from the three fixed-dose studies were pooled, analysis of fasting blood samples revealed that mean serum cholesterol and the low-density lipoprotein plus very-low-density lipoprotein cholesterol fraction were significantly (p less than or equal to 0.05) decreased during terazosin monotherapy (-5.4 mg/dl and -6.1 mg/dl, respectively) in comparison with placebo (-0.2 mg/dl and -1.0 mg/dl, respectively). Terazosin therapy was also associated with a significant within-group increase in the cholesterol ratio. In the dose-titration, comparative study, both terazosin- and prazosin-treated patients experienced significant within-group increases in the cholesterol ratio (1.8 and 2.3, respectively). Although changes in lipid parameters in the dose-titration comparative study were not significantly different between the three treatment groups, all changes in the tetrazosin and prazosin groups were in a beneficial direction, and were greater in magnitude than those observed in the placebo group. Observations from the four studies suggest that terazosin may exert a positive effect on the lipid profile.
    [Abstract] [Full Text] [Related] [New Search]